<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613089</url>
  </required_header>
  <id_info>
    <org_study_id>DEM-CHILD2020</org_study_id>
    <nct_id>NCT04613089</nct_id>
  </id_info>
  <brief_title>Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database</brief_title>
  <official_title>Natural History and Long Term Clinical Assessments of All Forms of Neuronal Ceroid Lipofuscinoses - Capturing Key Symptoms and Disease Progression as Part of the Independent, International NCL DEM-CHILD Patient Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study that aims at assessing the natural history of NCL diseases as&#xD;
      part of the international DEM-CHILD Database.&#xD;
&#xD;
        1. Patient data are collected from medical records, patient questionnaires and routine&#xD;
           follow up clinical examinations with focus on assessing progression in key areas of&#xD;
           disease such as motor, language, cognition, seizures, vision, and behavior.&#xD;
&#xD;
        2. A local biorepository of samples from genetically defined NCL patients will be&#xD;
           established as well as a virtual biorepository within the DEM-CHILD DB to be able to&#xD;
           easily localize international availability of patient samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NCLs (Neuronal Ceroid Lipofuscinoses) are a group of rare, inherited, neurodegenerative&#xD;
      disorders, also known as Batten disease. Until now, 13 different genes causing different&#xD;
      subtypes of disease are known. The genetic mutations cause a symptom complex of progressive&#xD;
      loss of acquired skills in the domains of motor function, cognition and visual function,&#xD;
      leading to ataxia, movement disorder, dementia, blindness and seizures. In the area of&#xD;
      genetic testing, variable clinical phenotypes become more and more prevalent. The&#xD;
      disease-mechanisms as well as the exact clinical course of the diseases are currently still&#xD;
      not fully understood and documented. Although descriptions of the clinical spectrums exist,&#xD;
      the natural history needs to be defined as accurately as possible. These data are urgently&#xD;
      needed as clinical control data helping to test the therapeutic efficacy of emerging&#xD;
      experimental therapies.&#xD;
&#xD;
      Since samples of genetically defined patients are rare and therefore limited for research,&#xD;
      there is an urgent need for researchers to localize and access samples internationally. With&#xD;
      the establishment of a local NCL-biorepository and virtual sample localization&#xD;
      internationally, scientists worldwide may have a faster way to access needed samples for&#xD;
      advancing research.&#xD;
&#xD;
      Any NCL patient with a confirmed molecular diagnosis can join the retrospective and&#xD;
      prospective natural history data collection. It is also possible for families with already&#xD;
      deceased patients to participate in the retrospective analysis part of the data collection if&#xD;
      the genetic mutation is known.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">April 8, 2050</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2050</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Identification of key symptoms of disease, natural history of disease progression and development of quantitative tools for rating disease progression that can be used as therapeutic outcome measures for emerging experimental therapies.</measure>
    <time_frame>Up to 30 years</time_frame>
    <description>Evaluation of Medical history from patient interviews and medical chart review. Evaluating data from clinical routine follow up exams (e.g. brain imaging MRI, ophthalmologic assessments, OCT, EEG, cardiology assessments, cognitive assessments, developmental scales, clinical rating scales).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish well characterized Natural History Cohorts from genetically defined NCL patients to provide these as Natural History Control Cohorts for new experimental therapy trials.</measure>
    <time_frame>Up to 30 years</time_frame>
    <description>Analysis of retrospective and prospective data from patient interviews and medical chart review as well as clinical routine follow up exams (e.g. brain imaging MRI, ophthalmologic assessments, OCT, EEG, cardiology assessments, cognitive assessments, developmental scales, clinical rating scales).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish a biorepository of samples from genetically defined NCL patients.</measure>
    <time_frame>Up to 30 years</time_frame>
    <description>- Collection of biospecimens that have been collected within treatment as part of standard of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish a virtual biorepository from genetically defined NCL patients within the DEM-CHILD Database.</measure>
    <time_frame>Up to 30 years</time_frame>
    <description>Datacollection of available biospecimens from genetically defined NCL patients and the collecting center contacts within the DEM-CHILD DB.</description>
  </secondary_outcome>
  <number_of_groups>14</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neuronal Ceroid Lipofuscinosis</condition>
  <condition>Batten Disease</condition>
  <condition>CLN1 Disease</condition>
  <condition>CLN2 Disease</condition>
  <condition>CLN3 Disease</condition>
  <condition>CLN4 Disease</condition>
  <condition>CLN5 Disease</condition>
  <condition>CLN6 Disease</condition>
  <condition>CLN7 Disease</condition>
  <condition>CLN8 Disease</condition>
  <condition>CLN10 Disease</condition>
  <condition>CLN11 Disease</condition>
  <condition>CLN12 Disease</condition>
  <condition>CLN13 Disease</condition>
  <condition>CLN14 Disease</condition>
  <arm_group>
    <arm_group_label>CLN1 Disease, Haltia-Santavuori Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN1/PPT1 gene, causing a lysosomal enzyme deficiency of PPT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN2 Disease, Jansky-Bielschowsky Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN2 Disease - ERT (Brineura) treated</arm_group_label>
    <description>Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1, previously and/or currently receiving enzyme-replacement therapy (ERT) with Cerliponase alpha (Brineura).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN3 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN4 disease, Parry disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN4/DNAJC5 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN5 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN5 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN6 Disease, Kufs Disease Type A</arm_group_label>
    <description>Patients with genetic mutations in the CLN6 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN7 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN7/MFSD8 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN8 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN8 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN10 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN10/CTSD gene, causing a lysosomal enzyme deficiency of Cathepsin D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN11 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN11/GRN gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN12 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN12/ATP13A2 gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN13 Disease, Kufs Disease Type B</arm_group_label>
    <description>Patients with genetic mutations in the CLN13/CTSF gene, causing a lysosomal enzyme deficiency of Cathepsin F.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLN14 Disease</arm_group_label>
    <description>Patients with genetic mutations in the CLN14/KCTD7 gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural History</intervention_name>
    <description>Natural History and Clinical Follow Up.</description>
    <arm_group_label>CLN1 Disease, Haltia-Santavuori Disease</arm_group_label>
    <arm_group_label>CLN10 Disease</arm_group_label>
    <arm_group_label>CLN11 Disease</arm_group_label>
    <arm_group_label>CLN12 Disease</arm_group_label>
    <arm_group_label>CLN13 Disease, Kufs Disease Type B</arm_group_label>
    <arm_group_label>CLN14 Disease</arm_group_label>
    <arm_group_label>CLN2 Disease - ERT (Brineura) treated</arm_group_label>
    <arm_group_label>CLN2 Disease, Jansky-Bielschowsky Disease</arm_group_label>
    <arm_group_label>CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease</arm_group_label>
    <arm_group_label>CLN4 disease, Parry disease</arm_group_label>
    <arm_group_label>CLN5 Disease</arm_group_label>
    <arm_group_label>CLN6 Disease, Kufs Disease Type A</arm_group_label>
    <arm_group_label>CLN7 Disease</arm_group_label>
    <arm_group_label>CLN8 Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All available Biomaterials from diagnostic approach and routine clinical care are collected&#xD;
      (e.g. blood, urine, skin cells, CSF, other..).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children, Adolescents, Adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with a confirmed molecular diagnosis of a form of NCL Disease&#xD;
&#xD;
        Additional inclusion criteria for Group/Cohort: &quot;CLN2 Disease - ERT (Brineura) Treated&quot;:&#xD;
&#xD;
          -  Documented diagnosis of TPP1 deficiency&#xD;
&#xD;
          -  Previous or current treatment with intracerebroventricular ERT with cerliponase alpha&#xD;
&#xD;
          -  Patients that are currently participating in post-marketing studies will be allowed to&#xD;
             participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients with no confirmed molecular diagnosis of a form of NCL Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Schulz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of NCL-Specialty Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Nickel, MD</last_name>
    <phone>+4940741020440</phone>
    <email>m.nickel@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Schulz, MD, PhD</last_name>
    <phone>+4940741020440</phone>
    <email>anschulz@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Nickel, MD</last_name>
      <phone>+4940741020440</phone>
      <email>m.nickel@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Angela Schulz, MD, PhD</last_name>
      <phone>+4940741020440</phone>
      <email>anschulz@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Schulz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Nickel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rietdorf K, Coode EE, Schulz A, Wibbeler E, Bootman MD, Ostergaard JR. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity. Biochim Biophys Acta Mol Basis Dis. 2020 Sep 1;1866(9):165643. doi: 10.1016/j.bbadis.2019.165643. Epub 2019 Dec 19. Review.</citation>
    <PMID>31863828</PMID>
  </reference>
  <reference>
    <citation>Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, Pagovich OE, Kosofsky B, Yohay K, Downs M, Slasor P, Ajayi T, Crystal RG, Kohlschütter A, Sondhi D, Schulz A. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018 Aug;2(8):582-590. doi: 10.1016/S2352-4642(18)30179-2. Epub 2018 Jul 2. Erratum in: Lancet Child Adolesc Health. 2018 Sep;2(9):e24.</citation>
    <PMID>30119717</PMID>
  </reference>
  <reference>
    <citation>Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D, Kohlschütter A; CLN2 Study Group. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018 May 17;378(20):1898-1907. doi: 10.1056/NEJMoa1712649. Epub 2018 Apr 24.</citation>
    <PMID>29688815</PMID>
  </reference>
  <reference>
    <citation>Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019 Nov;40(11):1924-1938. doi: 10.1002/humu.23860. Epub 2019 Jul 26.</citation>
    <PMID>31283065</PMID>
  </reference>
  <reference>
    <citation>Fietz M, AlSayed M, Burke D, Cohen-Pfeffer J, Cooper JD, Dvořáková L, Giugliani R, Izzo E, Jahnová H, Lukacs Z, Mole SE, Noher de Halac I, Pearce DA, Poupetova H, Schulz A, Specchio N, Xin W, Miller N. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016 Sep;119(1-2):160-7. doi: 10.1016/j.ymgme.2016.07.011. Epub 2016 Jul 25.</citation>
    <PMID>27553878</PMID>
  </reference>
  <reference>
    <citation>Simonati A, Williams RE, Nardocci N, Laine M, Battini R, Schulz A, Garavaglia B, Moro F, Pezzini F, Santorelli FM. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev Med Child Neurol. 2017 Aug;59(8):815-821. doi: 10.1111/dmcn.13473. Epub 2017 May 25.</citation>
    <PMID>28542837</PMID>
  </reference>
  <reference>
    <citation>Lebrun AH, Storch S, Rüschendorf F, Schmiedt ML, Kyttälä A, Mole SE, Kitzmüller C, Saar K, Mewasingh LD, Boda V, Kohlschütter A, Ullrich K, Braulke T, Schulz A. Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship. Hum Mutat. 2009 May;30(5):E651-61. doi: 10.1002/humu.21010.</citation>
    <PMID>19309691</PMID>
  </reference>
  <reference>
    <citation>Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los Reyes E, Denecke J, Drago K, Fairhurst C, Frazier M, Guelbert N, Kiss S, Kofler A, Lawson JA, Lehwald L, Leung MA, Mikhaylova S, Mink JW, Nickel M, Shediac R, Sims K, Specchio N, Topcu M, von Löbbecke I, West A, Zernikow B, Schulz A. Management Strategies for CLN2 Disease. Pediatr Neurol. 2017 Apr;69:102-112. doi: 10.1016/j.pediatrneurol.2017.01.034. Epub 2017 Feb 4. Review.</citation>
    <PMID>28335910</PMID>
  </reference>
  <reference>
    <citation>Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019 Apr;33(4):315-325. doi: 10.1007/s40263-019-00620-8. Review.</citation>
    <PMID>30877620</PMID>
  </reference>
  <reference>
    <citation>Löbel U, Sedlacik J, Nickel M, Lezius S, Fiehler J, Nestrasil I, Kohlschütter A, Schulz A. Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression. AJNR Am J Neuroradiol. 2016 Oct;37(10):1938-1943. doi: 10.3174/ajnr.A4816. Epub 2016 May 26.</citation>
    <PMID>27231226</PMID>
  </reference>
  <reference>
    <citation>Dulz S, Wagenfeld L, Nickel M, Richard G, Schwartz R, Bartsch U, Kohlschütter A, Schulz A. Novel morphological macular findings in juvenile CLN3 disease. Br J Ophthalmol. 2016 Jun;100(6):824-8. doi: 10.1136/bjophthalmol-2015-307320. Epub 2015 Oct 20.</citation>
    <PMID>26486417</PMID>
  </reference>
  <reference>
    <citation>Dulz S, Atiskova Y, Wibbeler E, Wildner J, Wagenfeld L, Schwering C, Nickel M, Bartsch U, Spitzer MS, Schulz A. An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 Disease. Am J Ophthalmol. 2020 Dec;220:64-71. doi: 10.1016/j.ajo.2020.07.015. Epub 2020 Jul 21.</citation>
    <PMID>32707205</PMID>
  </reference>
  <reference>
    <citation>Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Kleine Holthaus SM, McKay TR, Medina DL, Rahim AA, Schulz A, Smith AJ. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019 Jan;18(1):107-116. doi: 10.1016/S1474-4422(18)30368-5. Epub 2018 Nov 21. Review.</citation>
    <PMID>30470609</PMID>
  </reference>
  <reference>
    <citation>Bergholz R, Kohlschütter A, Schulz A, Hubert W, Rüther K. Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations. Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1245-50. doi: 10.1007/s00417-014-2814-0. Epub 2014 Oct 22.</citation>
    <PMID>25338278</PMID>
  </reference>
  <reference>
    <citation>Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801-6. doi: 10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17.</citation>
    <PMID>23602993</PMID>
  </reference>
  <reference>
    <citation>Paniagua Bravo A, Forkert ND, Schulz A, Löbel U, Fiehler J, Ding X, Sedlacik J, Rosenkranz M, Goebell E. Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis. Clin Neuroradiol. 2013 Sep;23(3):189-96. doi: 10.1007/s00062-012-0189-3. Epub 2012 Dec 23.</citation>
    <PMID>23263384</PMID>
  </reference>
  <reference>
    <citation>Kousi M, Anttila V, Schulz A, Calafato S, Jakkula E, Riesch E, Myllykangas L, Kalimo H, Topçu M, Gökben S, Alehan F, Lemke JR, Alber M, Palotie A, Kopra O, Lehesjoki AE. Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene. J Med Genet. 2012 Jun;49(6):391-9. doi: 10.1136/jmedgenet-2012-100859.</citation>
    <PMID>22693283</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Angela Schulz</investigator_full_name>
    <investigator_title>MD, PhD, Head of NCL Specialty Clinic</investigator_title>
  </responsible_party>
  <keyword>INCL</keyword>
  <keyword>LINCL</keyword>
  <keyword>VLINCL</keyword>
  <keyword>JNCL</keyword>
  <keyword>ANCL</keyword>
  <keyword>NCL</keyword>
  <keyword>CLN</keyword>
  <keyword>Batten</keyword>
  <keyword>Childhood Dementia</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Neurodegenerative Disorders</keyword>
  <keyword>Metabolic Disorders</keyword>
  <keyword>PME</keyword>
  <keyword>EPMR</keyword>
  <keyword>SCAR7</keyword>
  <keyword>SGSH</keyword>
  <keyword>PPT1</keyword>
  <keyword>Haltia-Santavuori Disease</keyword>
  <keyword>TPP1</keyword>
  <keyword>Jansky-Bielschowsky Disease</keyword>
  <keyword>Spielmeyer-Vogt-Sjögren-Batten Disease</keyword>
  <keyword>DNAJC5</keyword>
  <keyword>Parry Disease</keyword>
  <keyword>Kufs Disease Type A</keyword>
  <keyword>MFSD8</keyword>
  <keyword>CTSD</keyword>
  <keyword>GRN</keyword>
  <keyword>ATP13A2</keyword>
  <keyword>Kufor-Rakeb Syndrome</keyword>
  <keyword>CTSF</keyword>
  <keyword>Kufs Disease Type B</keyword>
  <keyword>KCTD7</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The goal of the independent international DEM-CHILD DB is to collect high quality natural history data of NCL patients. The independent nature of the database allows to make data available for international research on treatment evaluation and development.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_access_criteria>Upon written formal request. Project description of anticipated data usage needed. Specifications for exact data access (type of NCL, retrospective or prospective data, data items) and data transfer (one-time transfer, longitudinal access) must be declared. Data transfer agreements detailing the above will need to be in place with the respective data-entering center who has full data ownership.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

